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The double life of MULE in preeclamptic and
IUGR placentae
A Rolfo1, J Garcia1, T Todros2, M Post3,4,5 and I Caniggia*,1,3,6
The E3 ubiquitin ligase MULE (Mcl-1 Ubiquitin Ligases E3) targets myeloid cell leukemia factor 1 (Mcl-1) and tumor suppressor
p53 for proteasomal degradation. Although Mcl-1 and p53 have been implicated in trophoblast cell death in preeclampsia (PE)
and intrauterine growth restriction (IUGR), the mechanisms regulating their expression in the human placenta remains elusive.
Herein, we investigated MULE’s involvement in regulating Mcl-1 and p53 degradation during normal and abnormal (PE, IUGR)
placental development. MULE expression peaked at 5–7 weeks of gestation, when oxygen tension is low and inversely correlated
with that of Mcl-1 and p53. MULE efficiently bound to Mcl-1 and p53 and regulated their ubiquitination during placental
development. Exposure of first trimester villous explants to 3% O2 resulted in elevated MULE expression compared with 20% O2.
Low-oxygen-induced MULE expression in JEG3 choriocarcinoma cells was abolished by hypoxia-inducible factor (HIF)-1a
siRNA. MULE was overexpressed in both PE and IUGR placentae. In PE, MULE preferentially targeted p53 for degradation,
allowing accumulation of pro-apoptotic Mcl-1 isoforms. In IUGR, however, MULE targeted pro-survival Mcl-1, allowing p53 to
accumulate and exert its apoptotic function. These data demonstrate that oxygen regulates Mcl-1 and p53 stability during
placentation via HIF-1-controlled MULE expression. The different preferential targets of MULE in PE and IUGR placentae classify
early-onset PE and IUGR as distinct molecular pathologies.
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Preeclampsia (PE) and intrauterine growth restriction (IUGR)
are human pregnancy-related disorders that affect 3–7% and
5–10% of all pregnancies, respectively, and are one of the
leading causes of fetal and maternal mortality and mor-
bidity.1,2 PE manifests itself with a wide variety of maternal
symptoms including hypertension and proteinuria,3 whereas
IUGR is defined as failure of the fetus to achieve its
genetically-determined growth potential.2 The placenta plays
a key role in the genesis of both diseases. In PE-defective
remodeling of the maternal spiral arteries by trophoblast cells
is believed to be the cause for insufficient uteroplacental
circulation,4 leading to placental hypoxia5 and/or oxidative
stress,6,7 and in the most severe cases to fetal growth
restriction. IUGR may be caused by a variety of conditions
such as infections, maternal diseases and chromosomal
disorders, but more often, as in PE, its genesis is related to a
defect in proper placental development originating early in
pregnancy. Typical features of both severe IUGR and PE are
altered trophoblast cell proliferation and reduced chorionic
vessel development, leading to impaired angiogenesis.8
In addition, increased rates of trophoblast cell death
and turnover are characteristic for both pathologies.9–12
The underlying mechanisms for these changes in trophoblast
cell fate are unknown.
Bcl-2 family proteins form a complex network of cell death
inducers and suppressors that via their interactions determine
cell fate.13 Bcl-2 pro-apoptotic proteins act mainly by localiz-
ing permanently or transiently to the outer mitochondrial
membrane where they regulate or form pores. Opening of
these pores results in transitional changes in mitochondrial
membrane potential accompanied by release of death-
inducing factors from the mitochondria to the cytoplasm.
Pro-survival Bcl-2 family members act by keeping death-
inducing Bcl-2 proteins in an inactive state, thereby blocking
the decrease in mitochondrial membrane potential and
inhibiting the activation of the apoptotic cascade.14 The
balance between pro-survival and pro-apoptotic molecules
is tightly regulated and involves the ubiquitin–proteasome
system that targets specific proteins for degradation. Ubiqui-
tination requires the concerted action of three different
enzymes: E1 ubiquitin activators, E2 ubiquitin-conjugating
enzymes and E3 ubiquitin ligases that determine the
specificity of the process by recognizing the different
substrates.15 MULE (Mcl-1 Ubiquitin Ligases E3) is an E3
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ligase that specifically targets pro-survival Mcl-1L for ubiqui-
tination, thereby promoting its degradation via the protea-
some.16,17 Besides the classical HECT and ubiquitin-
associated domains typical of E3 ligases, MULE also contains
a Bcl-2 homology domain 3 (BH3) that functions as a specific
binding site for Mcl-1.16,17 In placentae from pregnancies
complicated by early-onset preeclampsia (E-PE) Mcl-1L
levels are decreased, while those of its pro-apoptotic spliced
variant Mcl-1S and its cleaved product Mcl-1c are
increased.18 Whether MULE plays a role in reducing Mcl-1L
levels in PE placentae remains to be elucidated. MULE also
targets c-Myc, CDC-6, E3Histone and, in particular, the tumor
suppressor protein p53 for ubiquitination.19 P53 plays a key
role in the rapid cellular response to stress20 and exerts its
anti-proliferative activity via a variety of mechanisms, includ-
ing cell cycle arrest, apoptosis and cellular senescence/aging.
Beside MULE, p53 protein stability is also regulated by two
other well-characterized ubiquitin ligases, such as murine
double minute-2 (Mdm2) and murine double minute-X
(MdmX).21,22 Expression of p53 is elevated in placentae
from pregnancies complicated by IUGR.9,12 As placental
pathologies, including PE and IUGR, are characterized by
altered expression of key regulators of trophoblast cell fate
such as Mcl-1 and p53, we hypothesized that changes in
MULE expression and activity may contribute to the altered
balance in pro-survival and death-inducing molecules typical
of these pathologies.
Results
MULE expression inversely correlates with that of Mcl-1
and p53. We first investigated the expression of MULE in
human placental tissue throughout early pregnancy. Real-
time PCR (Figure 1a) and western blot analysis (Figure 1b,
upper left panel) showed that MULE expression peaked at
5–7 weeks and declined with advancing gestation. In
agreement with our previous observations,26 Mcl-1 expres-
sion was maximal at 11–13 weeks of gestation (Figure 1b,
bottom left panel) and inversely correlated with that of MULE
(Pearson’s coefficient r¼  0.712). The specificity of the
MULE antibody was confirmed by western blot analysis using
MULE blocking-peptides. A 500 kDa band corresponding to
the main variant of MULE and its two main proteolytic
(approximately 240 and 270 kDa) products present in 293T
cell lysates23 were efficiently outcompeted (Figure 1b, right
panel). As MULE targets Mcl-1 for degradation, we examined
Mcl-1/MULE association and Mcl-1 ubiquitination. MULE
association to Mcl-1 was maximal at 5–6 weeks (Figure 1c,
right panel) and Mcl-1 ubiquitination peaked at 7–9 weeks
(Figure 1c, left panel): at the time when Mcl-1 levels are low
(Figure 1b, bottom left panel). As MULE has been shown to
target p53 for degradation, we also investigated p53
expression, p53/MULE association and p53 ubiquitination
during human placental development. Real-time PCR
showed no significant changes in p53 mRNA expression
throughout early placental development (not shown,
P40.10). In contrast, placental p53 protein expression
inversely correlated to that of MULE (Pearson’s coefficient
r¼  0.739), that is, low p53 protein levels at 5–7 weeks,
which increased with advancing gestation (Figure 1d, bottom
left panel). The association between p53 and MULE was
maximal at 5 and 6 weeks, whereas p53 ubiquitination levels
peaked around 7–9 weeks, as well as 12 and 13 weeks of
gestation (Figure 1d).
MULE, Mcl-1 and p53 placental localization. We then
examined the spatial localization of MULE and its targets
Mcl-1 and p53 in first trimester placental tissue. At 5 weeks of
gestation, a strong positive nuclear and cytoplasmic signal
for MULE was detected in cytotrophoblastic cells and to a
lesser extent in syncytiotrophoblast (ST) cells (Figure 2a). At
12 weeks of gestation, immunoreactivity for MULE was
markedly decreased in both trophoblast layers (Figure 2d).
This decrease in trophoblastic MULE signal at 12 weeks was
associated with major increases in immunoreactivity for Mcl-
1 (cytoplasm of ST cells) and p53 (nuclei of CT cells)
(Figures 2e and f). No positive immunoreactivity for MULE
was detected in section stained with control IgG (Figure 2g).
MULE oxygen-dependent expression is mediated by
HIF-1a. As MULE expression is high during the gestational
time of physiological low oxygenation, we examined its
regulation by oxygen using first trimester placental explants
exposed to 3% O2, standard 20% O2 or to hypoxia/
reoxygenation (HR). MULE protein levels were significantly
increased in low oxygen (3% versus 20% O2, P¼ 0.038, 8.6-
fold increase) and HR (HR versus 3% O2, P¼ 0.002, 3.5-fold
increase; HR versus 20% O2, P¼ 0.001, 30.7-fold increase)
(Figure 3a, upper left and right panels). Although exposure of
villous explants to 3% O2 resulted in increased Mcl-1L protein
levels, HR conditions showed a reduction of pro-survival Mcl-
1L (HR versus 20% O2, P¼ 0.04, 1.4-fold decrease)
(Figure 3a, middle left panel), in line with our previous
findings.18 Protein levels of p53 were unchanged among the
different conditions (Figure 3a, bottom left panel). As
hypoxia-inducible factor (HIF)-1a is a major player in the
physiological response to hypoxia, we next examined HIF-1a
protein expression during placental development and found
that it paralleled that of MULE (Figure 1b, left panel), showing
a peak of expression at 5–7 weeks that decreases with
advancing gestation (Figure 3b, right upper panel). Next, we
investigated whether MULE’s upregulation in low oxygen was
mediated via HIF-1a using HIF-1a siRNA. In preliminary
experiments, we observed that fluorescent-labeled siRNA
complexes efficiently (490%) transfected JEG3 cells and
that the relative lactate dehydrogenase (LDH) amount
released into the media (indication of toxicity) was compar-
able among siRNA-treated cells (D1 and D2), control
(scrambled sequence (SS)) siRNA-treated cells and control
cells treated with Lipofectamine 2000 vehicle alone (data not
shown). Real-time PCR showed that the HIF-1a gene was
efficiently silenced by both D1 and D2 siRNA duplexes
relative to control SS siRNA (D1 versus SS: 4.3-fold
decrease, P¼ 0.0095; D2 versus SS: 5.2-fold decrease,
P¼ 0.0095) (Figure 3b, left upper panel). Also, MULE mRNA
expression was significantly downregulated in HIF-1a siRNA-
treated cells relative to control SS siRNA-treated cells
(D1 versus SS: 1.7-fold decrease, P¼ 0.03; D2 versus SS:
1.8-fold decrease, P¼ 0.03) (Figure 3b, left bottom panel).
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These results were confirmed at the protein level, that is,
decrease of both HIF-1a and MULE protein levels in HIF-1a
siRNA (D1)-treated cells relative to control (untreated) cells
and cells treated with control SS siRNA (Figure 3b, bottom
right panel). Thus, conditions of low oxygen/oxidative
stress promote MULE accumulation via HIF-1a. We and
others reported that low oxygen promotes TGF-b3
expression via HIF-1 and that TGF-b3 is a key factor for
Figure 1 Expression and association of MULE, Mcl-1 and p53 during human placental development (5–7 weeks, n¼ 19; 8–10 weeks, n¼ 14; 11–15 weeks, n¼ 24).
(a) MULE mRNA expression during placental development assessed by real-time PCR (5–7 weeks, n¼ 7; 8–10 weeks, n¼ 6; 11–15 weeks, n¼ 12). Values are
mean±S.E.M., *Po0.05. (b) Representative immunoblots for MULE (upper left panel) and Mcl-1 (lower left panel) protein expression during placenta development
and MULE antibody validation (right panel) assessed by MULE immunoblot using 293T cells in the presence or absence of competing peptide (CP). (c) Representative
immunoblots for Mcl-1 ubiquitination (left panel) and MULE/Mcl-1 association (right panel) during placental development. (d) Representative immunoblots for p53
protein expression (left lower panel), ubiquitination (left upper panel) and MULE/p53 association (right panel) during placental development. (b and d) Actin immunoblots
demonstrates equal protein loading (5–7 weeks, n¼ 12; 8–10 weeks, n¼ 8; 11–15 weeks, n¼ 12)
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proper placentation.24–26 Hence, we next investigated
whether MULE expression was regulated by TGF-b3. We
found that TGF-b3, but not TGF-b1, markedly increased
MULE protein levels in placental villous explants (Figure 3c).
MULE, Mcl-1 and p53 expression in E-PE and IUGR
placentae. PE and IUGR are pathologies characterized by
placental hypoxia and increased trophoblast cell death and
turnover due to accumulation of pro-apoptotic molecules.
Hence, we examined MULE, Mcl-1 and p53 expression in
both disorders. MULE protein levels were increased in both
E-PE and IUGR placentae relative to age-matched controls
(AMCs) (Figure 4a, upper left and right panels). In line with
our previous observations,18 we found a significant decrease
in pro-survival Mcl-1L in E-PE placentae relative to AMC
controls (2.17-fold decrease, P¼ 0.0003; Figure 4a, left
panel). Total p53 protein levels were also significantly
decreased in E-PE placentae relative to AMC controls
(1.42-fold decrease, P¼ 0.0179) (Figure 4a, left panel),
whereas no significant changes in p53 mRNA levels were
found by real-time PCR analysis (not shown, P¼ 0.19). In
contrast, both p53 mRNA and protein levels were markedly
increased in IUGR placentae relative to AMC controls (p53
mRNA: 6.1-fold increase, P¼ 0.007; p53 protein: 1.5-fold
increase; Figure 4a, right panel). Notably, while in IUGR Mcl-
1L mRNA levels were significantly increased (2.35-fold
increase, P¼ 0.010), Mcl-1L protein levels were decreased
(2.3-fold decrease, P¼ 0.005) (Figure 4a, right panel). We
next investigated whether the differences in Mcl-1 and p53
protein expression between E-PE and IUGR placentae were
due to differences in MULE binding and ubiquitination of
these proteins. No apparent differences were found in Mcl-1/
MULE association, but Mcl-1 ubiquitination was slightly
elevated in E-PE versus AMC placentae (Figure 4b, left
panel). In contrast, p53/MULE association and p53 ubiqui-
tination were increased in E-PE placentae relative to AMC
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Figure 2 MULE, Mcl-1 and p53 spatial localization in first trimester human placental sections. MULE (a and d), Mcl-1 (b and e) and p53 (c and f) spatial localization at 5
and 12 weeks of gestation assessed by immunofluorescent staining (5–7 weeks, n¼ 7; 8–10 weeks, n¼ 6; 11–15 weeks, n¼ 12). Cell nuclei are showed in blue by DAPI
signal. ST, syncytiotrophoblast cells. Control IgG (g). Original magnifications,  20; insets,  100
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placentae (Figure 4c, left panel). In IUGR placentae, Mcl-1/
MULE association and Mcl-1 ubiquitination were increased
relative to AMC placentae (Figure 4b, right panel), whereas
p53/MULE association was reduced and ubiquitination of p53
was unchanged (Figure 4c, right panel). Terminal deoxynu-
cleotidyl transferase (TdT)-mediated dUTP nick-end labeling
(TUNEL) analysis confirmed the augmented levels of
trophoblast cell death in E-PE and IUGR placentae relative
to AMC (Figures 5a, b versus c). As anticipated, MULE’s
nuclear and cytoplasmic immunoreactivity in trophoblastic
cells was significantly increased in E-PE and IUGR placentae
relative to normotensive AMC controls (Figures 5d, e versus
f). Although cytoplasmic Mcl-1 immunoreactivity was slightly
reduced in the ST cells of E-PE placentae compared with
AMC placentae (Figure 5g versus i), hardly any signal was
detectable in IUGR placentae (Figure 5h versus i). The
nuclear p53 signal was markedly decreased in E-PE
placentae relative to controls (Figure 5j versus l), whereas
it was increased in the syncytium of IUGR placentae (Figure
5k versus l).
Discussion
PE and IUGR are serious disorders of pregnancy character-
ized by altered expression and function of pro- and anti-
apoptotic molecules, leading to increased rates of trophoblast
cell death and turnover. The precise mechanism(s) under-
pinning impaired cell fate in these placental pathologies
remain elusive. In this study, we demonstrate for the first time
that MULE, a novel E3 ubiquitin ligase,16,17,19 is temporally
and spatially expressed in the human placenta, where it
targets both pro-survival Mcl-1 and tumor suppressor p53 for
degradation. In addition, we show that MULE expression is
regulated by oxygen via HIF-1a and TGF-b3. Of clinical
relevance, we report aberrant MULE expression in severe
preeclamptic and IUGR placentae. Notably, our data
Figure 3 HIF-1a-mediated oxygen regulation of MULE expression. (a) Representative immunoblots for MULE, Mcl-1 and p53 protein expression in first trimester villous
explants (n¼ 18) exposed at 3% pO2, 20% pO2 and HR conditions (left panel). b-Actin immunoblot demonstrates equal protein loading. Densitometric analysis of MULE
protein levels at 20 and 3% pO2 and in condition of HR as assessed by western blot assay (right panel). Values are mean±S.E.M., *Po0.05. (b) HIF-1a and MULE (left
panels) mRNA expression levels in HIF-1a siRNA JEG-3 cells assessed by real-time PCR (values are mean±S.E.M., *Po0.05). Representative immunoblots for HIF-1a
protein expression during early placental development (right upper panel). Representative immunoblots for HIF-1a and MULE protein expression in siRNA JEG-3 cells (right
lower panels). Actin immunoblot demonstrates equal protein loading. (c) Representative MULE immunoblots in JEG-3 cells following exposure to TGF-b1/TGF-b3
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demonstrate that MULE differentially targets Mcl-1 and p53
for degradation in IUGR and preeclamptic placentae. Hence,
distinct mechanism(s) regulating Mcl-1 and p53 protein
stability, in part, contribute to the increased trophoblast cell
death and turnover typical of both pregnancy-related
disorders.
Bcl-2 proteins comprise a family of death-inducer and pro-
survival molecules, which by balancing their relative concen-
trations determine cell fate during development and normal
physiological conditions.13 Loss of this balance is central to a
variety of diseases including cancer- and pregnancy-related
disorders.11,18 Among Bcl-2 family members, pro-survival
Mcl-1 was first described as an ‘early induction’ gene27 and
later characterized as a potent antiapoptotic molecule.28
Disruption of Mcl-1 gene in mouse leads to pre-implantation
lethality implicating a role for Mcl-1 in early development.29 In
contrast, constitutive expression of Mcl-1 in transgenic mice
results in the development of hematological malignancies.28
Indeed, high levels of Mcl-1 in cancer are indicative of poor
prognosis. We previously demonstrated that a balance
between pro-survival Mcl-1 and its death-inducing partner
Mtd/Bok is essential in shaping proper placental development
and that an alteration in the Mcl-1/Mtd rheostat typifies
PE.11,18 Specifically, decreased pro-survival Mcl-1L expres-
sion (accompanied by accumulation of its pro-apoptotic
variants Mcl-1c and Mcl-1S) and elevated Mtd/Bok expres-
sion contributes to the aberrant trophoblast cell death seen in
this disorder.18
Mcl-1L is a very short-lived protein (t1/2¼ 2–4 h), belonging
to a group of immediate response genes upregulated in
immature cells upon exposure to differentiating agents and
antiapoptotic cytokines.30 Hence, Mcl-1 levels must be tightly
controlled to regulate cell survival. Mcl-1 protein stability and
activity are regulated by several mechanisms, including
synthesis, suppression via microRNA, phosphorylation,
caspases-mediated proteolysis and/or proteasomal degra-
dation.31–33 In addition, a recent study showed that
de-ubiquitinase USP9X inhibits Mcl-1 ubiquitination, thereby
stabilizing protein levels and promoting tumor cell survival.34
MULE, also known as ARF-BP1, UREB1, LASU1 and
a
b
c
Figure 4 MULE, Mcl-1 and p53 protein expression, MULE/Mcl-1-p53 association and Mcl-1/p53 ubiquitination levels in E-PE, IUGR and AMC placentae.
(a) Representative immunoblots for MULE, Mcl-1 and p53 in E-PE (n¼ 25, left panel) and IUGR (n¼ 18, right panel) versus AMC (n¼ 19) placentae. Actin immunoblot
demonstrates equal protein loading. (b) Representative immunoblots for MULE/Mcl-1 association and Mcl-1 ubiquitination (left panels) in E-PE (n¼ 25) versus AMC (n¼ 19)
placentae. Representative immunoblots for MULE/Mcl-1 association and Mcl-1 ubiquitination in IUGR (n¼ 18) versus AMC (n¼ 19) placentae (right panel). (c) (left panels).
Representative immunoblot for MULE/p53 association and p53 ubiquitination levels (left panels) in E-PE (n¼ 25) versus AMC (n¼ 19) placentae. Representative immunoblot
for MULE/p53 association and p53 ubiquitination levels in IUGR (n¼ 18) versus AMC (n¼ 19) placentae (right panels)
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E3histone, has been identified as the first E3 ligase that
specifically regulates Mcl-1L protein stability.16,17 MULE
possesses a BH3 domain that specifically recognizes and
binds to the BH3 domain located on Mcl-1, conferring MULE
specificity for this Bcl-2 protein.16 Because of its BH3 domain,
MULE can be considered a BH3-only pro-apoptotic protein;
however, its effect on cell death is indirect via regulation of
pro-survival Mcl-1 stability.16 Our findings of an inverse
correlation between Mcl-1L and MULE expression and the
temporal profiles of MULE binding to Mcl-1 and Mcl-1
ubiquitination highlight a role for MULE as a key regulator of
Mcl-1 stability during the early critical stages of placental
development. Later on in pregnancy, mechanisms other
than MULE-mediated proteasomal degradation may regulate
Mcl-1 stability. Indeed, we have previously reported that at the
end of first trimester, when MULE levels are lower, active
caspase-3 cleaves Mcl-1L, thereby generating pro-apoptotic
Mcl-1c.18
Besides binding to Mcl-1 and facilitating its degradation,
MULE also interacts with the tumor suppressor p53 and
promotes its proteasomal degradation.23 Similarly to Mcl-1L,
we found that MULE and p53 expression profiles during
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Figure 5 TUNEL assay and spatial localization of MULE, Mcl-1 and p53 in E-PE, IUGR and AMC human placental sections. TUNEL assay in placental sections from E-PE
(a), IUGR (b) and AMC (c). MULE (d–f; green), Mcl-1 (g–i; red) and p53 (j–l; red) spatial localization in E-PE, IUGR and AMC placental sections. ST, syncytium/
syncytiotrophoblast cells. Original magnifications,  20; insets,  100
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placental development are inversely correlated and that
MULE actively regulates p53 stability. It has been reported
that Mdm2 and MdmX are the primary E3 ligases targeting
p53 for degradation.21,22 However, MULE action on p53 is
Mdm2-independent19 and a simple inactivation of endogen-
ous MULE has been shown to stabilize and activate p53,19
indicating that MULE could possess a stronger affinity for p53
than Mdm2. In addition, recent in vitro studies conducted
using placental villous explants cultured in 1% O2 reported
that hypoxic conditions could stabilize p53 protein by inhibiting
its binding to Mdm2.35 Hence, it is plausible that Mdm2 may
account for p53 ubiquitination at 12 and 13 weeks of gestation
when MULE expression is low.
Subcellular localization studies in rat testis revealed that
nuclear MULE regulates p53 stability, while cytoplasmatic
MULE preferentially targets Mcl-1 for degradation.23 Our
observation of a nuclear and cytoplasmic localization of MULE
in both trophoblast cell layers at 5 weeks of gestation
implicates a role for this E3 ligase in regulating both p53 and
Mcl-1 stability during early human placental development.
Hence, early in pregnancy, MULE in part contributes to the
regulation of Mcl-1 and p53 homeostasis in a spatial and
temporal manner, thereby fine-tuning trophoblast cell fate.
Surprisingly, Mule association with both Mcl-1 and p53 was
high early on (5–6 weeks) in placentation, but ubiquitination of
Mcl-1 and p53 peaked at 7–9 weeks. We speculate that the
low ubiquitination levels of Mcl-1/p53 at 5–6 weeks seen in the
ubiquitination assay are due to the low amounts of Mcl-1 and
p53 protein present in the placental lysates. The low amount
of protein is likely due the rapid proteosomal degradation of
ubiquitinated Mcl-1/p53 at this particular gestation. The
placental lysates at 7–9 weeks contained relatively more
ubiquitinated Mcl-1/p53 protein. We hypothesize that the
proteosomal degradation machinery functions less efficient or
is maxed out at this particular gestational window, which
results in the accumulation of Mcl-1/p53 ubiquitinated earlier
(weeks 6 and 7). However, we have to clarify that the
developmental expression profiles of Mule, Mcl-1 and p53
represent a snap-shot in time of the in vivo scenario as human
placental tissues were snap-frozen immediately after delivery.
Thus, it is challenging to interpret from these findings the exact
dynamics of the processes taking place in vivo.
Oxygen acts as the driving force for proper placenta
development by regulating the expression of several genes
involved in trophoblast cell proliferation and death. A variety of
Bcl-2 family members, including Mcl-1,18 have been shown to
be directly regulated by oxygen via HIF-1. Here we show for
the first time that MULE expression in JEG-3 cells is regulated
by oxygen via HIF-1a. Moreover, MULE’s expression profile
in situ, that is, high expression at 5–7 weeks of gestation,
when oxygen tension is low, is consistent with oxygen-
mediated MULE regulation. Thus, MULE can be added to the
fast-expanding list of HIF-1 gene targets. Other E3 ligases
have also been shown to be regulated by oxygen. In 293T
cells, low oxygen directly induces the expression and
accumulation of Seven In Absentia Homologs 2 (Siah2), an
E3 ligase that positively regulates HIF-1a stability. In HeLa
and 293T cells, hypoxia is able to downregulate indirectly the
expression of the von Hippel–Lindau tumor suppressor
protein (targets HIF-1a for degradation in normoxic
conditions) via a post-transcriptional mechanisms that
involves APC/CCdh1 E3 ligases.36 In addition to being a
driving force in guiding proper placental development, oxygen
also plays a causal role in the etiopathogenesis of PE and
IUGR, and elevated HIF-1a expression in both pathologies is
central to the aberrant expression of molecules responsible
for altered trophoblast cell proliferation and death.5,37,38 Our
present observation of elevated MULE levels in E-PE and
IUGR placentae is consistent with placental hypoxia and
upregulated HIF-1a expression.5 Elevated HIF-1a levels
during early placental development and in E-PE are asso-
ciated with high levels of TGF-b3, a known HIF-1a target.24–26
These finding of MULE regulation by TGF-b3 further under-
scores the importance of the HIF/TGF-b3 axis in development
and disease of the human placenta.
Despite the fact that PE and IUGR are often clinically
associated and share several morphological and molecular
features indicative of altered cell death rates, it is still unclear
whether or not they are distinct pathologies. In this study, we
show for the first time that increased MULE expression in
placentae from severe preeclamptic pregnancies is asso-
ciated with low p53 and Mcl-1 levels. Importantly, our study
revealed that MULE preferentially binds and degrades p53 in
E-PE placentae, whereas in placentae from pure IUGR
pregnancies (with no clinical signs of hypertension) MULE
preferentially binds and targets Mcl-1L for degradation. Our
IUGR results agree with studies of others9,12 who reported
that augmented trophoblast apoptosis in IUGR pregnancies
was due to p53 accumulation and not to increased Bcl-2 pro-
apoptotic molecules.9,12 We recently reported that the
oxidative stress environment in severe PE placentae pro-
motes formation and accumulation of pro-apoptotic Mcl-1
variants (Mcl-1c), which are generated via a caspase-3-
mediated cleavage of pro-survival Mcl-1L.18 Hence, reduced
pro-survival Mcl-1L levels in E-PE placentae are primarily due
to cleavage by caspase-3. In contrast, reduced pro-survival
Mcl-1L in IUGR are likely due to increased MULE activity. This
differential regulation of two key molecules involved in cell fate
by MULE in placentae from IUGR and PE pregnancies
suggest that PE and IUGR are distinct molecular pathologies.
In conclusion, we demonstrate a role for MULE as regulator
of Mcl-1L and p53 stability during early placental develop-
ment. Furthermore, we provide evidence for a ‘double life’ of
MULE in placental pathologies. In PE, MULE selectively
targets p53 for degradation, thereby allowing accumulation of
pro-apoptotic Mcl-1 isoforms. Conversely in IUGR, increased
levels of MULE selectively promote degradation of pro-
survival Mcl-1L, whereas p53 levels increase.
Materials and Methods
Patient population and tissue collection. First and second trimester
human placenta tissues (5–7 weeks, n¼ 44; 8–10 weeks, n¼ 23, 11–15 weeks,
n¼ 39) were obtained from elective termination of pregnancies. Pathological
(PE and IUGR) and normotensive AMC placental samples were obtained after
informed consent in accordance with the ethics guidelines of University of Toronto
and Mount Sinai Hospital (Toronto, Canada) and O.I.R.M-Sant’Anna Hospital,
University of Turin (Turin, Italy). Patients clinical data are summarized in Table 1.
The study groups included singleton pregnancies complicated by severe E-PE
(n¼ 58) and pregnancies complicated by severe IUGR (n¼ 29) with abnormal
Doppler flow velocity waveforms in the umbilical artery (AEDF or REDF) and
without any evidence of maternal hypertensive disorder, renal disease or diabetes.
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The diagnosis of PE was made according to the following criteria: presence of
pregnancy-induced hypertension (systolic Z140mmHg, diastolic Z90mmHg)
and proteinuria (Z300mg/24 h) after the 20th week of gestation in previously
normotensive women.4 IUGR was defined as birth weight below the 3rd percentile
for gestational age and fetal sex, according to the local normograms. In all, 58
AMC placentae were obtained from normal pregnancies that did not show any
signs of PE, IUGR or other placental disease. Maternal age, gestational age and
parity were comparable between E-PE, IUGR and AMC groups; 19.6% of the
babies from E-PE pregnancies were growth restricted. Pregnancies with
congenital malformations, chromosomal anomalies (of number and/or structure)
or notable intrauterine infection were excluded from the study. Patients with
diabetes, infections and kidney disease were also excluded. Samples were
collected randomly from central and peripheral placental areas and snap frozen
immediately after delivery. Calcified, necrotic and visually ischemic areas were
excluded from collection.
RNA isolation and real-time PCR. Total RNA, extracted from placental
tissues and explant cultures,26 was treated with DNAse I to remove genomic DNA
contamination. Total RNA of 1 mg was reverse transcribed using random
hexamers (Applied Biosystems (ABI), Foster City, CA, USA). The resulting
templates (30 ng of cDNA for Mcl-1L, Mcl-1S, MULE, p53 and HIF-1a and 1.5 ng
for 18S) were quantified by real-time PCR (DNA Engine Opticon2 R system, MJ
Research, Waltham, MA, USA). TaqMan primers and probes for ribosomal 18S,
MULE, p53 and HIF-1a were purchased from ABI as Assays-on-Demand for
human genes. Quantitative PCR for Mcl-1 was performed using SYBR Green
(Bio-Rad Laboratories, Inc., Hercules, CA, USA) as described previously.18 For
each probe, a dilution series determined the efficiency of amplification of each
primer/probe set and the relative quantification method was employed.39 For the
relative quantitation, PCR signals were compared among groups after normal-
ization using 18S as internal reference. Relative expression and fold change was
calculated according to Livak and Schmittgen.39
Western blot analysis. Western blot analyses were performed as described
previously.40 Primary antibodies were rabbit polyclonal anti-human MULE (1:1500
dilution; Bethyl Laboratories, Montgomery, TX, USA), rabbit polyclonal anti-human
Mcl-1 (S-19; 1 : 500 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA),
goat polyclonal anti-human p53 (1 : 1000 dilution; Cell Signaling Technology,
Beverly, MA, USA) and rabbit polyclonal anti-human HIF-1a (1 : 1000; Cell
Signaling Technologies). Horseradish peroxidase-conjugated secondary antibo-
dies were donkey anti-rabbit for MULE (1 : 10 000), Mcl-1 (1 : 10 000), p53
(1 : 10 000) and HIF-1a (1 : 2000). Specificity of MULE antibody was determined
using MULE blocking-peptides (Bethyl Laboratories), while a 293T cell lysate was
used as positive control (Bethyl Laboratories).
Mcl-1/MULE and p53/MULE associations. The associations between
Mcl-1, p53 and MULE were examined as described previously.40 Following
immunoprecipitation of Mcl-1 or p53 using anti-Mcl-1 and anti-p53 antibodies,
respectively, imunoprecipitates were subjected to SDS-PAGE and immunoblotted
with anti-MULE antibody.
Mcl-1 and p53 ubiquitination. In all, 300mg of total protein was diluted in
RIPA buffer to a concentration of 1 mg/ml. Two micrograms of specific rabbit-
polyclonal Mcl-1 (Santa Cruz, S-19) or p53 (Cell Signaling) antibodies were added
to each sample and the mixtures were incubated at 4 1C on a rotator overnight. A
measure of 30ml of Protein-Aagarose beads (specific for IgG) were added to each
lysate and the mixture was incubated at 4 1C on a rotator for 2 h. Agarose beads
were collected by centrifugation and washed once with RIPA buffer and twice with
PBS. The beads were then resuspended in 2 SDS loading buffer, boiled for
5 min and centrifuged. The supernatants were collected, subjected to SDS-PAGE
and analyzed by western blotting using mouse monoclonal anti-human ubiquitin
antibody (1 : 500 dilution; Covance Research Products, Berkeley, CA, USA) in
TBST and 5% non-fat milk. A 1 : 10 000 dilution of anti-mouse–Ig–horseradish
peroxidase was used as secondary antibody. Immunoblots were visualized using
enhanced chemiluminescence.
Immunofluorescence staining. Placental tissues from first trimester
(5–12 weeks gestation, n¼ 25), PE (n¼ 15), IUGR (n¼ 10) and AMC (n¼ 15)
were fixed in 4% paraformaldehyde and embedded in paraffin. Before
immunofluorescence (IF) analysis, every 10th section was stained with
hematoxylin and eosin to assess the quality of the tissue and the most
representative sections were selected. Sodium citrate antigen retrieval was
performed, followed by Sudan Black treatment (0.1% Sudan Black in 70% EtOH)
to quench endogenous fluorescence. Sections were pre-incubated in 5% horse
serum in PBS (contained 0.04% sodium azide and 0.008% gelatin) to block
nonspecific binding and incubated with primary antibodies overnight at 4 1C.
Rabbit polyclonal antibodies anti-human MULE (1 : 400 dilution; Bethyl Labora-
tories), anti-human Mcl-1 (1 : 200 dilution; Santa Cruz Biotechnology) and anti-
human p53 (1 : 200 dilution; Cell Signaling Technologies) were used. Control IgG
were used as negative controls. Slides were treated with 0.4% DAPI (40,6-
diamidino-2-phenylindole) for nuclear detection. Fluorescence images were
viewed and captured using a DeltaVision Deconvolution microscope (Applied
Precision, LLC, Issaquah, WA, USA).
Human first trimester villous explant culture. First trimester (5–8
weeks of gestation, n¼ 18) villous explant cultures were established as described
previously.25 Villous explants were maintained in standard tissue culture conditions
of 5% CO2 in 95% air (20% O2 environment) or in an atmosphere of 3% O2/92%
N2/5% CO2 (3% O2 environment) for 48 h at 37 1C. These oxygen concentrations
were chosen because they represent the standard culturing condition and the
physiological placental low oxygen environment before 10 weeks of gestation,
respectively. In parallel experiments, explants were also exposed to HR as
described previously.11 In some experiments, villous explants were incubated with
5 ng/ml TGF-b1 or TGF-b3 for 48 h. For each treatment, tissue samples from the
same placenta were used and in each experiment, explant cultures were set up in
triplicate.
HIF-1a siRNA experiments. Human JEG-3 cells, cultured at 20% O2, were
transfected with 40 nM validated HIF-1a siRNA (Invitrogen, Carlsbad, CA, USA)
using Lipofectamine 2000. Scrambled siRNA sequences were used as negative
Table 1 Clinical features of the study population
Age-matched controls (n¼58) Early-onset preeclampsia (n¼58) IUGR (n¼ 29)
Mean maternal age (years) 33.4±4.8 29.9±5.2 29.8±5.3
Mean gestational age at delivery
(weeks (range))
29±3.3 (25–35) 28.6±2.86 (24–35) 31.5±1.2 (28–33)
Blood pressure (mm Hg) Systolic: 112±7.5
Diastolic: 68.7±5.7
Systolic: 175.5±16
Diastolic: 108±14.4
Systolic: 112.7±18.6
Diastolic: 75.5±6.5
Proteinuria (g/24 h) Absent 3.0±1 Absent
Fetal weight (g) AGA (n¼ 58): 1488.2±668.2 AGA (n¼48): 1250±387
IUGR (n¼10): 816.5±394
IUGR (n¼29): 1025±228
A/REDF (% of women) 0 0 100
Fetal sex Males¼45%
Females¼55%
Males¼ 66%
Females¼ 34%
Males¼56%
Females¼ 44%
Mode of delivery CS 41% VD 59% CS 90% VD 10% CS 100%
Abbreviations: AGA, appropriate for gestational age; IUGR, intra-uterine growth restriction; A/REDF, absent/reverse end diastolic flow of the umbilical arteries; VD,
vaginal delivery; CS, cesarean section delivery
Data are represented as mean±S.D.
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control and fluorescent-tagged siRNA duplexes were used to test transfection
efficiency. After transfection, cells were maintained at 3% O2 for 24 h before
mRNA and protein collection. To assess siRNA cytotoxicity, LDH release was
measured using the LDH-Cytotoxicity Assay Kit (Biovision Inc., Mountain View,
CA, USA) following the manufacturer’s instructions.
TUNEL assay. Programmed cell death in control, E-PE and IUGR placentae
was assessed by TUNEL as described previously.18 Briefly, tissue sections were
de-waxed, rehydrated and treated for 10min with 10 mg/ml proteinase K. Sections
were then treated with 0.1% Sudan Black, pre-incubated with 0.1% Triton X-100 in
OPA (One-Phor-All buffer, Pharmacia, Stockholm, Sweden), incubated for 90min
in TdT reaction mixture (TdT plus biotin-dUTP) and processed for IF using
streptavidin fluorescein. Images were captured using a DeltaVision Deconvolution
microscope (Applied Precision, LLC).
Statistical analysis. All data are presented as mean±S.E.M. For
comparison of data between multiple groups, we used one-way analysis of
variance (ANOVA) with post-hoc Dunnett’s test and Kruskal–Wallis one-way
ANOVA as appropriate. For comparison between two groups, we used paired and
unpaired Student’s t-test as appropriate. Correlations between groups was
calculated using Pearson’s coefficient. Statistical tests were carried out using
Prism statistical software and significance was accepted at Po0.05.
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